2014
AT-47PHASE I TRIAL OF INTRATHECAL TRASTUZUMAB IN HER2 POSITIVE LEPTOMENINGEAL METASTASES
Raizer J, Pentsova E, Omuro A, Lin N, Nayak L, Quant E, Kumthekar P. AT-47PHASE I TRIAL OF INTRATHECAL TRASTUZUMAB IN HER2 POSITIVE LEPTOMENINGEAL METASTASES. Neuro-Oncology 2014, 16: v19-v19. PMCID: PMC4217826, DOI: 10.1093/neuonc/nou237.46.Peer-Reviewed Original ResearchHER2-positive breast cancerPositive breast cancerLeptomeningeal metastasesDose levelsBreast cancerIntrathecal trastuzumabCentral nervous system penetrationPhase I clinical trialPhase II studyHumanized monoclonal antibodyIT trastuzumabMedian KPSII studyProgressive diseaseI trialMedian ageOmmaya reservoirCSF levelsAnaplastic ependymomaClinical trialsPatientsPK dataTherapeutic levelsIts TreatmentTrastuzumab
2012
Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer
Morris PG, Murphy CG, Mallam D, Accordino M, Patil S, Howard J, Omuro A, Beal K, Seidman AD, Hudis CA, Fornier MN. Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer. The Breast Journal 2012, 18: 345-350. PMID: 22607041, DOI: 10.1111/j.1524-4741.2012.01246.x.Peer-Reviewed Original ResearchConceptsBrain metastasesOverall survivalBreast cancerDiagnosis of BMIncidence of BMMedian age 53 yearsRisk of BMTriple-negative breast cancerActuarial median survivalLimited overall survivalAge 53 yearsGroup of patientsPatterns of recurrenceSingle-institution studyNegative breast cancerElectronic medical recordsBM diagnosisMedian survivalMetastatic diseaseEntire cohortRetrospective studyTherapeutic optionsInstitutional databaseMedical recordsModern therapy